Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
May 10, 2021
Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) - RMS2005 study
Heidi Glosli, Gianni Bisogno, Anna Kelsey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European <i>Paediatric</i> Soft Tissue Sarcoma Study Group RMS 2005 Trial
Gianni Bisogno, Julia Chisholm, Raquel Hladun, et al.
Cancer
|
February 7, 2025
Reply to "Toward a reduction in the burden of therapy in patients with rhabdomyosarcoma. How much is enough?"
Henry C Mandeville, Gianni Bisogno, Veronique Minard-Colin, et al.
Cancer
|
May 26, 2018
Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
Soledad Gallego, Ilaria Zanetti, Daniel Orbach, et al.
Cancer
|
July 26, 2024
Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial
Henry C Mandeville, Gianni Bisogno, Veronique Minard-Colin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 27, 2023
Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study
Gianni Bisogno, Veronique Minard-Colin, Ilaria Zanetti, et al.
Cancer
|
December 7, 2017
Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study
Bas Vaarwerk, Johanna H van der Lee, Willemijn B Breunis, et al.
The Lancet. Oncology
|
June 27, 2018
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial
Gianni Bisogno, Meriel Jenney, Christophe Bergeron, et al.
Communications Biology
|
February 28, 2024
Membrane lipids drive formation of KRAS4b-RAF1 RBDCRD nanoclusters on the membrane
Rebika Shrestha, Timothy S Carpenter, Que N Van, et al.
Communications Biology
|
April 11, 2024
Author Correction: Membrane lipids drive formation of KRAS4b-RAF1 RBDCRD nanoclusters on the membrane
Rebika Shrestha, Timothy S Carpenter, Que N Van, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
European Journal of Cancer (Oxford, England : 1990)
|
May 10, 2021
Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) - RMS2005 study
Heidi Glosli, Gianni Bisogno, Anna Kelsey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European <i>Paediatric</i> Soft Tissue Sarcoma Study Group RMS 2005 Trial
Gianni Bisogno, Julia Chisholm, Raquel Hladun, et al.
Cancer
|
February 7, 2025
Reply to "Toward a reduction in the burden of therapy in patients with rhabdomyosarcoma. How much is enough?"
Henry C Mandeville, Gianni Bisogno, Veronique Minard-Colin, et al.
Cancer
|
May 26, 2018
Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
Soledad Gallego, Ilaria Zanetti, Daniel Orbach, et al.
Cancer
|
July 26, 2024
Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial
Henry C Mandeville, Gianni Bisogno, Veronique Minard-Colin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 27, 2023
Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study
Gianni Bisogno, Veronique Minard-Colin, Ilaria Zanetti, et al.
Cancer
|
December 7, 2017
Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study
Bas Vaarwerk, Johanna H van der Lee, Willemijn B Breunis, et al.
The Lancet. Oncology
|
June 27, 2018
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial
Gianni Bisogno, Meriel Jenney, Christophe Bergeron, et al.
Communications Biology
|
February 28, 2024
Membrane lipids drive formation of KRAS4b-RAF1 RBDCRD nanoclusters on the membrane
Rebika Shrestha, Timothy S Carpenter, Que N Van, et al.
Communications Biology
|
April 11, 2024
Author Correction: Membrane lipids drive formation of KRAS4b-RAF1 RBDCRD nanoclusters on the membrane
Rebika Shrestha, Timothy S Carpenter, Que N Van, et al.
Page
of 9